Current NCCN and Japanese Breast Cancer Society (JBCS) guidelines in this subgroup do not include clear and standardized recommendations on the optimal treatment sequence or subsequent treatment options after CDK4/6 inhibitor therapy. This evidence concerns the gene CDK4 and breast carcinoma.